C.M.I.D. - Presidi Ospedalieri ASL 4
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Roccatello, Dario
Elixir, NCT03994471: Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

Recruiting
3
170
Europe
XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght, XyloCore 0.7 or 1.5 or 2.0, 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution, Physioneal 40 or 35, Fixioneal 40 or 35, Dianeal, Balance, Bicavera, Bicanova, Equibalance
Iperboreal Pharma Srl
End Stage Renal Disease
12/24
12/24
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Recruiting
3
160
Europe, Canada, Japan, US, RoW
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
GlaxoSmithKline
Eosinophilic Granulomatosis With Polyangiitis
10/25
11/25
AL38, NCT06571864: AL Amyloidosis and Anti-CD38-Daratunumab

Completed
N/A
14
Europe
Anti-CD38 Monoclonal Antibody
University of Turin, Italy
Amyloidosis
01/24
02/24

Download Options